FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) is set to present a range of new clinical data at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024), which will take place from March 3-6. The data encompasses nearly eighty studies, including late-breaking findings and four oral presentations, covering advancements in HIV, COVID-19, and viral hepatitis treatments.
The research includes an evaluation of Biktarvy® as a long-term HIV treatment option, particularly for patients with comorbidities. Additionally, the company will discuss investigational therapies such as a once-weekly oral combination of islatravir and lenacapavir and the combination of lenacapavir with broadly neutralizing antibodies for potential long-acting treatment regimens.
In the realm of COVID-19, Gilead will present real-world evidence analyses, including the impact of Veklury® (remdesivir) on mortality among immunocompromised individuals hospitalized during the Omicron wave. Studies on racial and ethnic disparities in COVID-19 treatment initiation and the effects of Veklury on long-COVID will also be highlighted.
For viral hepatitis, new data will be shared on the safety and efficacy of Hepcludex® in individuals with HIV, HBV, and HDV coinfections, based on a 96-week analysis from the Phase 3 MYR301 study.
The conference presentations reflect Gilead's ongoing commitment to biomedical innovation in virology, aiming to address the diverse needs of those affected by challenging viruses globally. This includes exploring long-acting treatment options and preventive measures, as well as seeking to treat, prevent, and potentially eradicate viral diseases.
While many compounds such as lenacapavir, teropavimab, and others remain investigational and await approval from regulatory authorities, lenacapavir is already approved in several countries under the brand name Sunlenca® for treating multi-drug resistant HIV in combination with other antiretrovirals.
Gilead Sciences emphasizes that there is no cure for HIV or AIDS, and the safety and efficacy of the investigational compounds presented at CROI 2024 have not been established.
The information shared in this article is based on a press release statement from Gilead Sciences, Inc.
InvestingPro Insights
As Gilead Sciences, Inc. (NASDAQ:GILD) showcases its latest clinical advancements at the prestigious CROI 2024 conference, investors may find it useful to look at some key metrics and insights provided by InvestingPro. With a market capitalization of $91.86 billion and a notably low P/E ratio of 12.09 for the last twelve months as of Q4 2023, Gilead stands out in the biotechnology industry. This low P/E ratio, especially relative to near-term earnings growth, suggests that the company may be undervalued, which is an InvestingPro Tip highlighting a potential investment opportunity.
Another InvestingPro Tip for Gilead is its track record of raising its dividend for 9 consecutive years, showcasing a commitment to returning value to shareholders. This is further bolstered by a strong dividend yield of 4.19%. Additionally, Gilead's free cash flow yield is implied to be robust, indicating that the company generates ample cash relative to its share price.
Investors should note the company's financial health and stability, as evidenced by a gross profit margin of nearly 78% and operating income margin of 36.48% for the last twelve months as of Q4 2023. These margins reflect Gilead's efficiency in managing its operations and profitability.
For those interested in further insights and tips, InvestingPro offers additional guidance on Gilead Sciences, with a total of 11 InvestingPro Tips available at https://www.investing.com/pro/GILD. Don't forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.